BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 202 USD | +4.56% |
|
+3.50% | -21.94% |
| Apr. 24 | Health Care Down Amid Mixed Earnings -- Health Care Roundup | DJ |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
202
USD
Average target price
291.2
USD
Spread / Average Target
+44.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.94% | 28.08B | |
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B | |
| +2.09% | 7.72B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen : to Conduct Phase 3b Study of Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi
